The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
← catalyst calendarNCT06909773 · readout in 70 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Diagnostic
Enrollment
3,000estimated
Sites
85
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-28 | actual | When the study began enrolling |
| Primary completion | 2026-10-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiovascular Diseases
Intervention
- Behavioral: Guideline education and implementation intervention
Primary outcome
what the primary-completion date above is the date OFThe number and percentage of COPD in participants with CVD,CHD,AF,CHF.
measured Baseline
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed